BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 23

Viridian Therapeutics Inc

VRDNNASDAQ
Trade with Public
Trade with Public
$22.12
0.542.5%
가까이에: Sep 22, 5:00 PM EST
$22.56
0.441.99%
시간외: 5:18 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Viridian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viridian Therapeutics (VRDN).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy
14Buy
2Hold
Consensus RatingBuy# Analysts17Avg. Consensus PT$37Upside to Avg. PT+65.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 22, 2026RBC CapitalLisa WalterPT RaiseOutperform$36→$38
Aug 7, 2026RBC CapitalLisa WalterPT RaiseOutperform$35→$36
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved